google13e27bb2df3cf8c9.html
  1. Breaking through the barriers to deliver efficacious and safe treatments for patients suffering from Pain
  2. Breaking through the barriers to deliver efficacious and safe treatments for patients suffering from Pain
  3. Add Your Title Here
  4. Add Your Title Here

      Novel Therapies forTreating Pain ...Without Compromise
  ​
News: On November 20, 2017, the U.S. Patent Office indicated that U.S. Patent Application Serial No. 15/699,856 contained allowable subject matter.  This application is part of MAXONA’s patent strategy for MAX-001 and once issued should provide patent protection until September 2037.  
  ​​
MAXONA Pharmaceuticals is committed to leveraging an ex-U.S. marketed non-Opioid, non-NSAID analgesic as a New Molecular Entity for the treatment of acute and chronic pain in the United States. 

While the U.S. is currently experiencing an opioid abuse epidemic, there has been very limited innovation to address the needs of millions of Americans suffering from acute and chronic pain. Hence, there is a significant need for safe and efficacious alternative analgesics. MAXONA has identified a molecule which aims to fundamentally address the short-comings of existing therapies. ​


News & Events:

​​On November 20, 2017, the U.S. Patent Office indicated that U.S. Patent Application Serial No. 15/699,856 contained allowable subject matter.  This application is part of MAXONA’s patent strategy for MAX-001 and once issued should provide patent protection until September 2037.

​​MAXONA will be attending the J.P.Morgan Healthcare Conference January 8-11, 2018 - San Francisco, CA

Shawn Fatholahi, President & CEO of MAXONA Pharmaceuticals, will be presenting a company update at the Biotech Showcase investors conference, on Wednesday January 10th, 2018 at 11:00 AM (PST) in the Franciscan A ballroom of the Hilton San Francisco Union Square Hotel - San Francisco, CA.